Effectiveness of pathogenetic therapy of patients with Parkinson’s disease in the Kursk Region

Abstract

INTRODUCTION: Analysis of the effectiveness of treatment for the disease is necessary to improve the medical care provided to the given category of patients.

AIM: To determine the effectiveness of pathogenetic therapy of patients with Parkinson’s disease (PD) in the population of the Kursk region depending on age and stage according to the Hoehn–Yahr Rating Scale, and to assess the severity of the disease depending on gender and place of residence.

MATERIALS AND METHODS: A total of 100 outpatients with a mixed form of PD aged 45–74 years (of them are 60 women and are 40 men) were examined. The mean age of the patients was 62.7 ± 6.2 years. Most patients lived in the rural region — 61.0% (32 women and 29 men), while 39.0% (28 women and 11 men) lived in the urban area. The severity of the disease was assessed according to the Hoehn–Yahr scale. Cognitive function was studied using the MMSE scale (Mini-Mental State Examination), the Frontal Assessment Battery (FAB), and the Clock Drawing test.

RESULTS: The age of PD onset varied from 42 to 70 years (mean age 58.5 ± 6.7 years); in rural residents — 58.8 ± 6.9 years (in men — 58.6 ± 5.6 years, in women — 58.9 ± 5.8 years); in urban residents — 58.2 ± 6.5 years (in men — 57.1 ± 5.4 years, in women — 58.6 ± 6.9 years); p > 0.05. Monotherapy with L-DOPA drugs was effective in 50.0% of cases, and with dopamine receptor agonists (DRA) in 53.0% of cases, combination therapy with DRA and L-DOPA preparations appeared to be more effective and made 72.5% of cases.

CONCLUSION: In the studied cohort of patients with Parkinson’s disease, patients living in rural areas outnumbered the urban patients 1.5 times, however, the mean age of onset was comparable. Therapy for patients with Parkinson’s disease was staged consisting in prescribing monotherapy at the early stages of the disease with subsequent replacement with a combination of dopamine receptor agonists and levodopa. The greatest treatment efficiency in patients with a mixed form of Parkinson's disease is observed with combination therapy.

Keywords

Parkinson's disease / neurodegenerative disease / pathogenetic therapy / monotherapy / combination therapy / neuropsychological testing / age

References

[1] Tolosa E, Garrido A, Scholz SW, et al. Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 2021;20(5):385–97. doi: 10.1016/s1474-4422(21)00030-2

[2] Tolosa E., Garrido A., Scholz S.W., et al. Challenges in the diagnosis of Parkinson's disease // Lancet Neurol. 2021. Vol. 20, No. 5. P. 385–397. doi: 10.1016/s1474-4422(21)00030-2

[3] Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med. 2020; 36(1):1–12. doi: 10.1016/j.cger.2019.08.002

[4] Simon D.K., Tanner C.M., Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology // Clin. Geriatr. Med. 2020. Vol. 36, No. 1. P. 1–12. doi: 10.1016/j.cger.2019.08.002

[5] Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021; 397(10291):2284–303. doi: 10.1016/s0140-6736(21)00218-x

[6] Bloem B.R., Okun M.S., Klein C. Parkinson's disease // Lancet. 2021. Vol. 397, No. 10291. P. 2284–2303. doi: 10.1016/s0140-6736(21)00218-x

[7] Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996): 896–912. doi: 10.1016/s0140-6736(14)61393-3

[8] Kalia L.V., Lang A.E. Parkinson's disease // Lancet. 2015. Vol. 386, No. 9996. P. 896–912. doi: 10.1016/s0140-6736(14)61393-3

[9] Illarioshkin SN. Modern view on etiology of Parkinson's disease. Nevrologicheskiy Zhurnal. 2015;20(4):4–13. (In Russ).

[10] Иллариошкин С.Н. Современные представления об этиологии болезни Паркинсона // Неврологический журнал. 2015. Т. 20, № 4. С. 4–13.

[11] Rybkina VL, Azizova TV. The Risk factors of Parkinson’s Disease. Nevrologicheskiy Zhurnal. 2017;22(6):287–94. (In Russ).

[12] Рыбкина В.Л., Азизова Т.В. Факторы риска развития болезни Паркинсона // Неврологический журнал. 2017. Т. 22, № 6. С. 287–294.

[13] Gaponov DO, Prigodina EV, Grudina TV, et al. Modern view on the pathogenetic mechanisms of Parkinson’s disease progression. RMJ. 2018;12(1):66–72. (In Russ).

[14] Гапонов Д.О., Пригодина Е.В., Грудина Т.В., и др. Современный взгляд на патогенетические механизмы прогрессирования болезни Паркинсона // РМЖ. 2018. Т. 12, № 1. С. 66–72.

[15] Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson's disease: progress and therapeutic implications. Mov Disord. 2013;28(1): 14–23. doi: 10.1002/mds.25249

[16] Singleton A.B., Farrer M.J., Bonifati V. The genetics of Parkinson's disease: progress and therapeutic implications // Mov. Disord. 2013. Vol. 28, No. 1. P. 14–23. doi: 10.1002/mds.25249

[17] Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91(8):795–808. doi: 10.1136/jnnp-2019-322338

[18] Jankovic J., Tan E.K. Parkinson's disease: etiopathogenesis and treatment // J. Neurol. Neurosurg. Psychiatry. 2020. Vol. 91, No. 8. P. 795–808. doi: 10.1136/jnnp-2019-322338

[19] Levin OS, Artemyev DV, Bril EV, et al. Parkinson’s disease: modern approaches to diagnosis and treatment. Practical Medicine. 2017;1(1):45–51. (In Russ).

[20] Левин О.С., Артемьев Д.В., Бриль Е.В., и др. Болезнь Паркинсона: современные подходы к диагностике и лечению // Практическая медицина. 2017. Т. 1, № 1 (102). С. 45–51.

[21] Levin OS, Datieva VK. Tremor in Parkinson’s disease: features of the phenomenology and treatment. Sovremennaya Terapiya v Psikhiatrii i Nevrologii. 2014;(3):14–9. (In Russ).

[22] Левин О.С., Датиева В.К. Тремор при болезни Паркинсона: особенности феноменологии и лечения // Современная терапия в психиатрии и неврологии. 2014. № 3. С. 14–19.

[23] Kicherova OA, Reikhert LI. Cognitive impairment in Parkinson's disease. Medical Science and Education of Ural. 2018;19(4):183–6. (In Russ).

[24] Кичерова О.А., Рейхерт Л.И. Когнитивные нарушения при болезни Паркинсона // Медицинская наука и образование Урала. 2018. Т. 19, № 4 (96). С. 183–186.

[25] Melyokhin AI. Ispol’zovaniye testa risovaniya chasov v skrining-obsledovanii kognitivnogo defitsita. Natsional’nyye Prioritety Rossii. 2014;(2):186–98. (In Russ).

[26] Мелёхин А.И. Использование теста рисования часов в скрининг-обследовании когнитивного дефицита // Национальные приоритеты России. 2014. № 2 (12). С. 186–198.

[27] Mazurenko EV, Ponomarev VV, Sakovich RA. Cognitive impairments in Parkinson’s disease. Meditsinskie Novosti. 2014;(1):6–11. (In Russ).

[28] Мазуренко Е.В., Пономарев В.В., Сакович Р.А. Когнитивные нарушения при болезни Паркинсона // Медицинские новости. 2014. № 1. С. 6–11.

[29] Elsworth JD. Parkinson's disease treatment: past, present, and future. J Neural Transm (Vienna). 2020;127(5):785–91. doi: 10.1007/s00702-020-02167-1

[30] Elsworth J.D. Parkinson's disease treatment: past, present, and future // J. Neural. Transm. (Vienna). 2020. Vol. 127, No. 5. P. 785–791. doi: 10.1007/s00702-020-02167-1

[31] Jagadeesan AJ, Murugesan R, Vimala Devi S, et al. Current trends in etiology, prognosis and therapeutic aspects of Parkinson's disease: a review. Acta Biomed. 2017;88(3):249–62. doi: 10.23750/abm.v88i3.6063

[32] Jagadeesan A.J., Murugesan R., Vimala Devi S., et al. Current trends in etiology, prognosis and therapeutic aspects of Parkinson's disease: a review // Acta Biomed. 2017. Vol. 88, No. 3. P. 249–262. doi: 10.23750/abm.v88i3.6063

[33] Schrag A, Hovris A, Morley D, et al. Young-versus older-onset Parkinson's disease: impact of disease and psychosocial consequences. Mov Disord. 2003;18(11):1250–6. doi: 10.1002/mds.10527

[34] Schrag A., Hovris A., Morley D., et al. Young-versus older-onset Parkinson's disease: impact of disease and psychosocial conse-quences // Mov. Disord. 2003. Vol. 18, No. 11. P. 1250–1256. doi: 10.1002/mds.10527

[35] Fedorova NV. Parkinson’s Disease: Diagnosis and Treatment. Sovremennaya Terapiya v Psikhiatrii i Nevrologii. 2016;(1):13–7. (In Russ).

[36] Фёдорова Н.В. Болезнь Паркинсона: диагностика и лечение // Современная терапия в психиатрии и неврологии. 2016. № 1. С. 13–17.

RIGHTS & PERMISSIONS

Eco-Vector